Saturday 17 October 2026
Export BCTX’s income statement to Excel — free account
BRIACELL THERAP
BCTX Healthcare Biotechnology
In the quarter to April 2026, EPS grew 94.0% and free cash flow was flat, each against the same quarter a year earlier.
3.42
0.35
−9.28%
Follow BCTX
| Jul '25 | Jul '24 | Jul '23 | Jul '22 | Jul '21 | Jul '20 | Jul '19 | Jul '18 | Jul '17 | Jul '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
5.01 | 0.49 | 14.96 | 45.00 | 103.80 | 0.07 | 0.15 | 1.40 | 1.84 | 17.14 |
Net Debt/EBITDA |
0.66 | 0.03 | 0.91 | 2.69 | 8.23 | 0.01 | (0.03) | 0.17 | 0.63 | 0.49 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 72.54% | 49.05% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.47) | 1.19 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.07 | 5.04 | 1.17 | 0.47 | 0.56 | 0.31 | 0.88 | 0.92 | 0.59 | 0.71 |
Capex/Depreciation |
0.00 | (5.44) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | (25.69) | (15,288.90) | (88.75) | (133.54) | (198.33) | (244.28) | — | — |
| (359.23%) | 148.30% | (619.76%) | (141.26%) | (114.78%) | 189.99% | (2,667.58%) | (508.50%) | (327.70%) | (164.96%) | |
| (191.21%) | (29.01%) | (58.22%) | (53.35%) | (47.18%) | (860.95%) | (317.98%) | (219.39%) | (205.57%) | (151.89%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (754.89%) | 0.00% | 0.00% |
Return on Tangible Assets |
(161.97%) | 140.14% | (80.73%) | (64.82%) | (24.14%) | 108.70% | 488.44% | (772.93%) | (345.31%) | (215.95%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.01 | 0.03 | 0.01 | 0.01 | 0.00 | 0.50 | 0.62 | 0.12 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(66.58) | (224.09) | (227.88) | (120.86) | (257.48) | (263.73) | (1,012.82) | (1,390.89) | (655.68) | (622.95) |
Cash per Share |
42.23 | 7.86 | 203.95 | 397.31 | 1,902.61 | 4.42 | 38.34 | 639.39 | 690.27 | 426.32 |
Shareholders Equity per Share |
40.97 | (24.47) | (36.25) | 99.99 | 919.33 | (749.46) | (168.21) | 345.39 | 320.41 | 408.89 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
40.97 | (24.47) | (36.25) | 99.99 | 919.33 | (749.46) | (168.21) | 345.39 | 320.41 | 408.89 |
Free Cash Flow |
(28.17) | (24.58) | (23.74) | (12.48) | (7.75) | (1.27) | (3.85) | (3.89) | (1.44) | (1.18) |
Working Capital |
15.95 | (3.81) | 25.15 | 41.41 | 57.24 | (3.70) | (0.90) | 0.55 | 0.70 | 0.77 |
Capital Expenditures |
— | (0.46) | — | — | — | — | — | — | 0.00 | 0.00 |
Net Current Asset Value |
15.61 | (4.90) | (3.99) | 10.10 | 27.43 | (3.86) | (0.90) | 0.55 | 0.70 | 0.77 |
| Other line items | ||||||||||
Quick Ratio |
5.01 | 0.49 | 14.96 | 43.64 | 102.88 | 0.01 | 0.14 | 1.32 | 1.83 | 16.93 |
Depreciation/Fixed assets |
0.36 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.25 |
Cash ROIC |
(80.03%) | 1,348.63% | (135.89%) | (24.30%) | (9.12%) | 35.40% | 1,981.82% | (99.75%) | (64.88%) | (74.59%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(66.58) | (219.93) | (227.88) | (120.86) | (257.48) | (263.73) | (1,012.82) | (1,390.89) | (655.68) | (622.95) |
Capex per Share |
0.00 | (4.16) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
2.43 | 4.24 | 2.86 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.02 |
Average Payables |
5.23 | 4.15 | 0.79 | 0.34 | 1.96 | 2.23 | 0.49 | 0.29 | 0.21 | 0.09 |
Average Assets |
13.76 | 16.52 | 34.87 | 50.31 | 29.28 | 0.47 | 1.38 | 1.94 | 1.18 | 1.10 |
Average Common Equity |
7.32 | (3.23) | 3.28 | 19.00 | 12.04 | (2.12) | 0.16 | 0.84 | 0.74 | 1.01 |
Capex to Sales |
— | 0.00 | — | — | — | — | — | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026